Seminars in Hematology
Volume 37, Issue 1 , Pages 30-42 , January 2000

Current status of allogeneic bone marrow transplantation in acquired aplastic anemia

  • Mary M Horowitz

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Mary M. Horowitz, MD, MS, Health Policy Institute, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226.

References 

  1. Anasetti C, Doney KC, Storb R, et al.  Marrow Transplantation for severe aplastic anemia: Long-term outcome in fifty ‘untransfused’ patients. Ann Intern Med. 1986;104:461–466
  2. Anasetti C, Storb R, Longton G, et al.  Donor buffy-coat cell infusion after marrow transplantation for aplastic anemia. Blood. 1988;72:1099–1100 (letter)
  3. Andrykowski MA, Bruehl S, Brady MJ, et al.  Physical and psychosocial status of adults one-year after bone marrow transplantation: A prospective study. Bone Marrow Transplant. 1995;15:837–844
  4. Appelbaum FR, Cheever MA, Fefer A, et al.  Recurrence of aplastic anemia following cyclophosphamide and syngeneic bone marrow transplantation: Evidence for two mechanisms of graft failure. Blood. 1985;65:553–556
  5. Appelbaum FR, Fefer A, Cheever MA, et al.  Treatment of aplastic anemia by bone marrow transplantation in identical twins. Blood. 1980;55:1033–1038
  6. Azuma E, Kokima S, Kato K, et al.  Conditioning widi cyclophosphamide/antithymocyte globulin for allogeneic bone marrow transplantation from HLA-matched siblings in children with severe aplastic anemia. Bone Marrow Transplant. 1997;19:1085–1087
  7. Bacigalupo A, Hows J, Gluckman E, et al.  Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT Working Party. Br J Haematol. 1988;70:177–182
  8. Barrett AJ, Young NS. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367–3377
  9. Bean MI, Storb R, Graham T, et al.  Prevention of transfusion-induced sensitization to minor histocompatibility antigens on DLA-identical canine marrow grafts by gamma irradiation of marrow donor blood. Transplantation. 1991;52:956–960
  10. Bensinger WI, Weaver CH, Appelbaum FR, et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85:1655–1658
  11. Björkholm M. Aplastic anaemia: Pathogenetic mechanisms and treatment with special reference to immunomodulation. J Intern Med. 1992;231:575–582
  12. Bortin MM, Rimm AA. Treatment of 144 patients with severe aplastic anemia using immunosuppression and allogeneic marrow transplantation: A report from the International Bone Marrow Transplant Registry. Transplant Proc. 1981;8:227–229
  13. Bortin MM, Rimm AA, For the Advisory Committee of the Bone Marrow Transplant Registry . Bone marrow transplantation from histocompatible, allogeneic donors for aplastic anemia: A report from the ACS/NIH Bone Marrow Transplant Registry. JAMA. 1976;236:1131–1135
  14. Bortin MM, Ringdén O, Horowitz MM, et al.  Temporal relationship between the major complications of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989;4:339–344
  15. Bron D. Grafr-versus-host disease. Curr Opin Oncol. 1994;6:358–364
  16. Bunin N, Leahy A, Kamani N, et al.  Bone marrow transplantation in pediatric patients with severe aplastic anemia: cyclophosphamide and antithymocyte globulin conditioning followed by recombinant human granulocyte-macrophage colony stimulating factor. J Pediatr Hematol Oncol. 1996;18:68–71
  17. Camitta BM, Thomas ED, Nathan DG, et al.  Severe aplastic anemia: A prospective study of the effect of early marrow transplantation on acute mortality. Blood. 1976;48:63–70
  18. Castro-Malaspina H, Childs B, Laver J, et al.  Hyperfractionated total lymphoid irradiation and Cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. Int J Radiat Oncol Biol Phys. 1994;29:847–854
  19. Champlin RE, Feig SA, Sparkes RS, et al.  Bone marrow transplantation from identical twins in the treatment of aplastic anemia: Implication for the pathogenesis of the disease. Br J Haematol. 1984;56:455–463
  20. Champlin RE, Ho WG, Nimer SD, et al.  Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide, low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy. Transplantation. 1990;49:720–724
  21. Champlin RE, Horowitz MM, van Bekkum DW, et al.  Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. Blood. 1989;73:606–613
  22. Clement-DeBoers A, Oostdijk W, van Weel-Sipman MH, et al.  Final height and hormonal function after bone marrow transplantation in children. J Pediatr. 1996;129:544–550
  23. Colby C, Stoukides CA, Spitzer TR. Antithymocyte globulin in severe aplastic anemia and bone marrow transplantation. Ann Pharmacotherapy. 1996;30:1164–1174
  24. Curtis RE, Rowlings PA, Deeg HJ, et al.  Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  25. de Souza MHO, Diamond HR, Silva MLM, et al.  Immunological recovery after bone marrow transplantation for severe aplastic anaemia: A Brazilian experience. Eur J Haematol. 1994;53:150–155
  26. Deeg HJ, Leisenring W, Storb R, et al.  Long-term outcome after marrow transplantation for severe aplastic anemia. Blood. 1998;91:3637–3645
  27. Deeg HJ, Socié G, Schoch G, et al.  Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: A joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392
  28. Deeg HJ, Storb R, Thomas ED, et al.  Cyclosporine as prophylaxis for graft-versus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood. 1985;65:1325–1334
  29. Doney K, Leisenring W, Storb R, et al.  Primary treatment of acquired aplastic anemia: Outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med. 1997;126:107–115
  30. Feig SA, Champlin R, Arenson E, et al.  Improved survival following bone marrow transplantation for aplastic anemia. Br J Haematol. 1983;54:509–517
  31. Gale RP, Bortin MM, van Bekkum DW, et al.  Risk factors for acute graft-vs-host disease. Br J Haematol. 1987;67:397–406
  32. Gluckman E, Horowitz MM, Champlin RE, et al.  Bone marrow transplantation for severe aplastic anemia: Influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79:269–275
  33. Gluckman E, Socie G, Devergie A, et al.  Bone marrow transplantation in 107 patients with severe aplastic anemia using cyclophosphamide and thoraco-abdominal irradiation for conditioning: Long-term follow-up. Blood. 1991;78:2451–2455
  34. Glucksberg H, Storb R, Fefer A, et al.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304
  35. Gordon-Smith EC, Fairhead SM, Chipping PM, et al.  Bone marrow transplantation for severe aplastic anemia using histocompatible unrelated volunteer donors. Br Med J. 1982;285:835–837
  36. Gratwohl A, Hermans J, Apperley J, et al.  Acute graft-versus-host disease: Grade and outcome in patients with chronic myelogenous leukemia. Blood. 1995;86:813–818
  37. Guinan EC. Clinical aspects of aplastic anemia. Hematol Oncol Clin North Am. 1997;11:1025–1044
  38. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, et al.  Results of bone marrow transplants from genetically-identical twins into patients with aplastic anemia. Ann Intern Med. 1997;126:116–122
  39. Horstmann M, Stockschläder M, Krüger W, et al.  Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: Preliminary results. Ann Hematol. 1995;71:77–81
  40. Hows JM, Marsh JC, Yin JL, et al.  Bone marrow transplantation for severe aplastic anaemia using cyclosporin: Long-term follow-up. Bone Marrow Transplant. 1989;4:11–16
  41. Hows JM, Yin JL, Marsh J, et al.  Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anemia and leukemia. Blood. 1986;68:1322–1328
  42. Kalhs P, White JS, Gervassi A, et al.  In vitro recall of proliferative and cytolytic response to minor histocompatibility antigens by dendritic cell enriched canine peripheral blood mononuclear cells. Transplantation. 1995;59:112–118
  43. Kernan NA, Bartsch G, Ash RC, et al.  Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. N Engl J Med. 1993;328:593–602
  44. Korbling M, Przepiorka D, Huh YO, et al.  Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood. 1995;85:1659–1665
  45. Lu D-P. Syngeneic bone marrow transplantation for treatment of aplastic anemia: Report of a case and review of the literature. Exp Hematol. 1981;9:257–263
  46. Margolis D, Camitta B, Pietryga D, et al.  Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol. 1996;94:65–72
  47. Marmont AM, Horowitz MM, Gale RP, et al.  T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78:2120–2130
  48. Martin PJ, Schoch G, Fisher L, et al.  A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood. 1990;76:1464–1472
  49. May WS, Sensenbrenner LL, Burns WH, et al.  BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant. 1993;11:459–464
  50. McCann SR, Bacigalupo A, Gluckman E, et al.  Graft rejection and second bone marrow transplants for acquired aplastic anaemia: A report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant. 1994;13:233–237
  51. McGlave PB, Haake R, Miller W, et al.  Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood. 1987;70:1325–1330
  52. Paquette RL, Tebyani N, Frane M, et al.  Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: Comparison with bone marrow transplantation. Blood. 1995;85:283–290
  53. Passweg JR, Socié G, Hinterberger W, et al.  Bone marrow transplantation for severe aplastic anemia: Has outcome improved?. Blood. 1997;90:858–864
  54. Pillow RP, Epstein RB, Buckner CD, et al.  Treatment of bone marrow failure by isogeneic marrow infusion. N Engl J Med. 1966;275:94–97
  55. Ramsay NK, Kim TH, McGlave P, et al.  Total lymphoid irradiation and cyclophosphamide conditioning prior to bone marrow transplantation for patients with severe aplastic anemia. Blood. 1983;62:622–626
  56. Ringdén O, Horowitz MM, Sondel P, et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. Blood. 1993;81:1094–1101
  57. Robins MM, Noyes WD. Aplastic anemia treated with bone-marrow infusion from identical twin. N Engl J Med. 1961;265:974–979
  58. Rowlings PA, Przepiorka D, Klein JP, et al.  IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855–864
  59. Sagmeister M, Oec L, Gmür J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood. 1999;93:3124–3126
  60. Sanders JE, The Seattle Marrow Transplant Unit . The impact of marrow transplant preparative regimens on subsequent growth and development. In: ed 2. Semin Hematol. 28:1991;p. 244–249
  61. Sanders JE, Storb R, Anasetri C, et al.  Marrow transplant for children with severe aplasric anemia. Am J Pediatr Hematol Oncol. 1994;16:43–49
  62. Schmitz N, Bacigalupo A, Labopin M, et al.  Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation. Br J Haematol. 1996;95:715–723
  63. Schmitz N, Dreger P, Suttorp M, et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood. 1995;85:1666–1672
  64. Smith BR, Guinan EC, Parkman R, et al.  Efficacy of a cyclophosphamide-procarbazine-antithymocyte serum regimen for prevention of graft rejection following bone marrow transplantation for transfused patients with aplastic anemia. Transplantation. 1985;39:671–673
  65. Socie G, Henry-Amar M, Cosset JM, et al.  Increased incidence of solid malignant tumors after bone marrow transplantation for severe aplastic anemia. Blood. 1991;787:277–279
  66. Socié G, Scieux C, Gluckman E, et al.  Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia. Transplantation. 1998;66:667–670
  67. Socié G, Veum-Stone J, Wingard JR, et al.  Long-term survival and late deaths after allogeneic bone marrow transplantation: implications for cure. N Engl J Med. 1999;341:14–21
  68. Speck B, Gluckman E, Haak HL, et al.  Treatment of aplastic anemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2:1145–1148
  69. Storb R. Bone marrow transplantation for aplastic anemia. Cell Transplant. 1993;2:365–379
  70. Storb R, Deeg HJ, Farewell V, et al.  Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68:119–125
  71. Storb R, Deeg HJ, Thomas ED, et al.  Marrow transplantation for chronic myelocytic leukemia: A controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood. 1985;66:698–702
  72. Storb R, Deeg HJ, Whitehead J, et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–735
  73. Storb R, Doney KC, Thomas ED, et al.  Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood. 1986;59:236–246
  74. Storb R, Epstein RB, Rudolph RH, et al.  The effect of prior transfusion on marrow grafts between histocompatible canine siblings. J Immunol. 1970;105:627–633
  75. Storb R, Etzioni R, Anasetti C, et al.  Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  76. Storb R, Floersheim GL, Weiden PL, et al.  Effect of prior blood transfusions of marrow grafts: Abrogation of sensitization by procarbazine and antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  77. Storb R, Leisenring W, Anasetti G, et al.  Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood. 1997;89:3890–3891
  78. Storb R, Leisenring W, Deeg HJ, et al.  Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood. 1994;83:2749–2756
  79. Storb R, Pepe M, Anasetti C, et al.  What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?. Blood. 1990;76:1037–1045
  80. Storb R, Prentice RL, Thomas ED, et al.  Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anemia. Br J Haematol. 1983;55:573–585
  81. Storb R, Prentice RL, Thomas ED, et al.  Marrow transplantation of aplastic anemia: An analysis of factors associated with graft rejection. N Engl J Med. 1977;296:61–66
  82. Storb R, Thomas ED, Buckner CD, et al.  Allogeneic marrow grafting for treatment of aplastic anemia. Blood. 1974;43:157–180
  83. Storb R, Thomas ED, Buckner CD, et al.  Marrow transplantation in thirty “untransfused” patients with severe aplastic anemia. Ann Intern Med. 1980;92:30–36
  84. Storek J, Gooley T, Siadak M, et al.  Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood. 1997;90:4705–4709
  85. Sullivan KM. Long-term follow-up and quality of life after hematopoietic stem cell transplantation. J Rheumatol. 1997;24:S46–S52
  86. Sullivan KM, Deeg HJ, Sanders J, et al.  Hyperacute graft-versus-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood. 1986;67:1172–1175
  87. Thomas ED, Storb R, Fefer A, et al.  Aplastic anemia treated by marrow transplantation. Lancet. 1972;1:284–289
  88. Urbano-Ispizua A, Garcia-Conde J, Brunet S, et al.  High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. Haematologica. 1997;82:683–689
  89. Vogelsang GB. Acute graft-versus-host disease. In:  Champlin R editors. Bone Marrow Transplantation. Boston, MA: Kluwer Academic; 1990;p. 55–77
  90. Wingard J. Functional ability and quality of life of patients after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1994;14:S29–S33
  91. Young N. Autoimmunity and its treatment in aplastic anemia. Ann Intern Med. 1997;126:166–168
  92. Young NS. Aplastic anaemia. Lancet. 1995;346:228–232
  93. Zapatero A, Marín A, López M, et al.  Successful bone marrow transplantation in sensitized aplastic anemia patients using total lymphoid irradiation for conditioning: Long-term follow-up. Hematol Oncol. 1996;14:165–172

PII: S0037-1963(00)90028-3

Seminars in Hematology
Volume 37, Issue 1 , Pages 30-42 , January 2000

Article Tools